Lung cancer

Non-small cell lung cancer
#Biomarkers #Lung cancer #Merck #Oncology #Phase II trial #Precision medicine #Regulatory #Scottish Medicines Consortium (SMC)

SMC approves targeted treatment for lung cancer

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.  … Read More

#News #Regulatory

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

#Biologics / Biotechnology #Cancer research #Collaboration #Europe #Gene therapy #Lung cancer

International consortium launches €12.8 million lung cancer project

Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.   The project gathers European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy. Over the next three years, the consortium… Read More

#Cancer Research #News

#Chemotherapy #Lung cancer

NICE recommendation a step-change for rare and aggressive type of lung cancer 

The National Institute for Health and Care Excellence (NICE) has published a positive recommendation for Takeda’s EXKIVITY (mobocertinib) for treating EGFR Exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy within a Final Appraisal Document (FAD).1,2  In March 2022, Great Britain was the first… Read More

#News

SITC 2022 Logo
#Cancer research #Lung cancer #Oncology #Society for Immunotherapy of Cancer #Trial data

Immutep shares encouraging trial data at SITC 2022

Immutep has revealed encouraging initial clinical data from two trials investigating its lead product candidate eftilagimod alpha in non-small-cell lung cancer.  Findings from the trials were shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022.   The INSIGHT-003 trial is evaluating eftilagimod alpha… Read More

#Cancer Research #News

Small cell lung cancer
#Cancer research #Cancer treatment #Lung cancer

Combination therapy halts lung cancer tumour growth in mice

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a recent study. The discovery was made by researchers at Washington University School of Medicine in St Louis, Grenoble Alpes University in Grenoble in France, and The University… Read More

#Cancer Research #News

#Drug approvals #Lung cancer #Takeda

Takeda’s cancer drug gets nod from MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Takeda’s EXKIVITY (mobocertinib) for patients in Great Britain with a rare and aggressive form of non-small cell lung cancer (NSCLC).   The authorisation means that EXKIVITY (mobocertinib) will be made available as a… Read More

#News

#Cancer #Lung cancer #Therapeutics

Partnership identifies novel small molecule inhibitors for lung cancer  

Arctoris and Evariste Technologies have formed a joint venture to identify novel small molecule kinase inhibitors for treatment of patients with Non-Small Cell Lung Cancer (NSCLC).   Current treatment options  Current treatment options for NSCLC are limited, especially in advanced stages. It has been shown that… Read More

#News

Lung cancer
#AstraZeneca #Lung cancer #Oncology

Success for AstraZeneca lung cancer therapy 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1  Context  Lung… Read More

#News #Trending News

#Cancer research #Lung cancer #Oncology

Scottish milestone for potential lung cancer treatment 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC) for the treatment of early-stage lung cancer.   Osimertinib will be used as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have… Read More

#Cancer Research #News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #Imaging #Lung cancer #Oncology

CIAN Lung: Exploring the potential of real-world data in lung cancer research

This article is sponsored by BC Platforms. Lung cancer ranks among the most prevalent and fatal cancers worldwide, prompting the need for improved treatment outcomes. Effective management relies on understanding tumour characteristics, including histology, clinical staging, and biomarkers. Despite progress in targeted therapies, ongoing research is… Read More

#News